By Administrator_India
The Drugs Controller General of India has approved of the commercial launch of ‘Feluda’, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Covid-19 test, the Council of Scientific and Industrial Research (CSIR) said recently.
This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement.
The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use. CRISPR is a genome editing technology to diagnose diseases.
You may also like
-
COVID-19 Vaccine Tracker: Over 1.61 lakh people receive coronavirus vaccine on February 23
-
Barbados PM writes to PM Modi, thanks India for Covid-19 vaccine doses
-
Testing blitz shows Australian coronavirus cluster contained in Sydney’s northeast
-
EU states to start vaccinations against Covid-19 from December 27
-
With 8593 new COVID-19 cases Delhi records highest single-day spike
